Zanolimumab

{{short description|Human monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 470635574

| image =

| type = mab

| mab_type = mab

| source = u

| target = CD4

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 652153-01-0

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = HG3L8885M0

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D06356

| chemical_formula =

| molecular_weight = 147

| molecular_weight_comment = kg/mol

}}

Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug.{{cite journal | vauthors = Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C | title = Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome | journal = Expert Opinion on Biological Therapy | volume = 8 | issue = 12 | pages = 1929–39 | date = December 2008 | pmid = 18990079 | doi = 10.1517/14712590802528696 | s2cid = 58115371 }} It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,{{cite web|url=http://www.tenxbiopharma.com/development.shtml |title=TenX BioPharma |access-date=August 20, 2010 |url-status=dead |archive-url=https://web.archive.org/web/20100411114420/http://www.tenxbiopharma.com/development.shtml |archive-date=April 11, 2010 }} cutaneous and peripheral T-cell lymphoma.[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab] {{Webarchive|url=https://web.archive.org/web/20110604015208/http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc |date=2011-06-04 }}, American Medical Association.{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}} Development of the drug was ultimately discontinued with termination of all trials.{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|access-date=6 November 2011|archive-date=27 May 2013|archive-url=https://web.archive.org/web/20130527120616/http://clinicaltrials.gov/search/intervention=Zanolimumab|url-status=live}}